OJR520

**OJR520** is an investigational small molecule drug developed by Novartis for the treatment of chronic kidney disease (CKD). It is currently in a first-in-human Phase 1 clinical trial (NCT07235059) evaluating safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) in healthy volunteers and CKD patients not on dialysis or transplant. The trial involves single and multiple ascending doses compared to placebo, with early preclinical data suggesting it targets novel pathways involved in kidney damage to potentially preserve kidney function beyond standard therapies like ACE inhibitors or ARBs. Detailed mechanism of action, specific targets, and efficacy data remain undisclosed at this early stage.[1][5][7]